The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS & spliceosome mutations
Samuel Urrutia, MD, Washington University in St. Louis, St. Louis, MO, comments on a study investigating the causes of death in patients with myelodysplastic syndromes (MDS) and spliceosome mutations. Dr Urrutia notes that the study elucidated that the IPSS-M classification, based on mutational profile, was better at stratifying patients by risk of transformation to acute myeloid leukemia (AML) than the IPSS-R classification, which is based on cytogenetics. While some patients classified as low-risk by IPSS-R experienced transformation to AML, zero transformations were observed in IPSS-M low-risk patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yes, so this is an interesting study that we did in collaboration with the McGovern Medical School. So, in this study, we looked at 427 patients with splicing mutations, and we looked at their causes of death, and we were interested in looking at the difference in causes of death between IPSS-R, the classification based on cytogenetics, and IPSS-M, which is a classification based on mutational profile...
Yes, so this is an interesting study that we did in collaboration with the McGovern Medical School. So, in this study, we looked at 427 patients with splicing mutations, and we looked at their causes of death, and we were interested in looking at the difference in causes of death between IPSS-R, the classification based on cytogenetics, and IPSS-M, which is a classification based on mutational profile.
So one of the interesting findings in the study is that the stratification between lower- and higher-risk MDS is much better for IPSS-M. And we can see this reflected in the causes of death. So to give you an example, patients who are IPSS-M high risk, as many expect, would transform into AML. And after transforming to AML, they would have an event, meaning dying. But patients who are classified as IPSS-R low, would sometimes have this as well. So that’s a little bit confusing because we would think that patients who have low-risk MDS wouldn’t transform to AML as likely as patients who are high-risk.
And so by applying IPSS-M to the same cohort of patients, we were able to see that IPSS-M is able to categorize patients who are at risk of transforming to AML much better. We saw zero transformations in IPSS-M low, meaning that it’s a much better surrogate for the ability of MDS to proliferate into AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ascentage: Consultancy
